Izervay (avacincaptad pegol)
Research Synopsis
- - Izervay (avacincaptad pegol) is a complement C5 inhibitor recently approved for treating geographic atrophy related to age-related macular degeneration (AMD).
- - Clinical trials (GATHER1 and GATHER2) demonstrated that avacincaptad pegol can significantly reduce the progression of geographic atrophy lesions, with a 27-28% reduction noted over 12 months in initial studies.
- - The drug was generally well tolerated among participants, with no serious adverse events reported during the trials, indicating promising safety profiles.
- - Research has shown that while avacincaptad pegol slows disease progression, it does not improve visual acuity, which remains a critical concern.
- - Some studies indicate that avacincaptad pegol may increase the risk of macular neovascularization, posing potential complications for patients.
- - Comparative analysis with other treatments, like pegcetacoplan (a C3 inhibitor), highlights the efficacy of avacincaptad pegol in reducing GA growth, although both treatments have limitations.
- - The sentiment surrounding avacincaptad pegol is cautiously optimistic, emphasizing the need for continued research to evaluate long-term effectiveness and patient impact.
- - Recent literature reflects a shift towards targeting the complement system for AMD treatment, which may lead to further advancements in managing this condition.
- - The first approval of avacincaptad pegol is viewed as a significant milestone in the pursuit of effective therapies for geographic atrophy, yet underscores the necessity for ongoing clinical trials to enhance therapeutic outcomes.
- - There is increasing interest in individualized patient care approaches for GA treatment, addressing patient preferences and treatment tolerability for optimizing outcomes with compounds like avacincaptad pegol.
Izervay (avacincaptad pegol)
Stargardt macular dystrophy and evolving therapies.
London, UK
2 hours ago
1 Received
- Stargardt macular dystrophy (STGD1) is a hereditary eye condition with no effective treatments currently available, prompting research into various therapeutic options.
- Investigational therapies focus on reducing toxic substances in the retina and include potential treatments like C20-D3-vitamin A, isotretinoin, and a complement inhibitor named avacincaptad pegol, although they have shown mixed results in animal studies and lack human efficacy proof.
- Experts suggest that stem cell transplantation, gene therapy targeting the ABCA4 gene, and visual cycle modulators could be promising approaches, but more clinical trials are needed to evaluate their safety and effectiveness in humans.
$100 - $150
Hourly Rate
Complement inhibition as a therapeutic strategy in retinal disorders.
London, UK
2 hours ago
1 Received
- - Dry age-related macular degeneration (AMD) and Stargardt Macular Dystrophy (STGD1) both lead to vision loss due to macula deterioration, with inflammation linked to the complement system being a key factor in these diseases.
- - Several treatments targeting this complement system have been tested, with mixed results; for example, lampalizumab and eculizumab did not prove effective in halting disease progression, while APL-2 showed promise in reducing growth.
- - Despite setbacks in clinical trials, ongoing research into new complement inhibitors and gene therapy approaches remains important for addressing these conditions and improving future treatment options.
$100 - $150
Hourly Rate
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
London, UK
2 hours ago
1 Received
- The study aimed to evaluate the safety and efficacy of avacincaptad pegol (Zimura), a C5 inhibitor, in treating geographic atrophy (GA) related to age-related macular degeneration (AMD).
- It was a significant clinical trial (GATHER1) involving 286 participants, with results showing a 27-28% reduction in GA growth over 12 months for both dose groups compared to a sham group.
- The treatment was generally well tolerated, with no serious adverse events reported, leading to plans for a follow-up study (GATHER2) to further confirm its effectiveness and safety.
$100 - $150
Hourly Rate
Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial (Ophthalmology. 2021;128:576-586).
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration (Ophthalmology. 2021;128:576-586).
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Investigational drugs in clinical trials for macular degeneration.
London, UK
2 hours ago
1 Received
- Intravitreal anti-VEGF injections are effective for treating exudative AMD but require frequent administration and some patients do not respond, highlighting the need for new treatments, especially for geographic atrophy AMD.
- The paper discusses the causes of macular degeneration, evaluates current and failed treatments, and explores new therapies in clinical trials, assessing their potential for success.
- Promising future therapies for exudative AMD focus on more effective and long-lasting inhibition of the VEGF pathway, while for geographic atrophy, targeting retinal cell phagocytosis and complement activity appears most promising, with some complement inhibitors likely to gain FDA approval soon.*
$100 - $150
Hourly Rate
Complement inhibitors for age-related macular degeneration.
London, UK
2 hours ago
1 Received
- Age-related macular degeneration (AMD) is a major cause of vision loss globally, linked to overactivity in the complement system, and currently has no effective treatments for most patients.
- Recent research has focused on developing complement inhibitors as potential new therapies for AMD, leading to the first randomized controlled trials in this area.
- The review analyzed ten trials with over 4000 participants, assessing the safety and effectiveness of these inhibitors based on various visual and quality-of-life outcomes over one year.
$100 - $150
Hourly Rate
COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHY: Review of Salient Functional Outcomes and Perspective.
London, UK
2 hours ago
1 Received
- The study assessed the efficacy of two complement inhibitors, pegcetacoplan and avacincaptad pegol, in treating geographic atrophy by examining data from recent randomized trials.
- Pegcetacoplan showed a significant reduction in autofluorescence loss with monthly dosing, but no functional improvement in vision, while avacincaptad pegol also reduced autofluorescence loss without enhancing visual acuity.
- Both treatments increased the risk of macular neovascularization, suggesting they may have drawbacks despite showing some imaging benefits.
$100 - $150
Hourly Rate
The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy.
London, UK
2 hours ago
1 Received
- * Current research is focused on developing therapies that target inflammation, the complement system, and neuroprotective mechanisms to slow or reverse the progression of geographic atrophy.
- * Promising therapies, including FDA-approved complement inhibitors like pegcetacoplan and avacincaptad pegol, are being explored, along with new strategies such as optogenetic therapy, to enhance our understanding and treatment of AMD.
$100 - $150
Hourly Rate
Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology.
London, UK
2 hours ago
1 Received
- Aptamers are short DNA or RNA molecules that are effective in targeting specific proteins, making them valuable for diagnosing and treating eye disorders, though research in this area is still emerging.
- Recent studies have evaluated aptamer-related drugs, like pegaptanib and others, that target factors such as TGF-β and VEGF to prevent complications in conditions like glaucoma and age-related macular degeneration.
- This review highlights the ongoing development of aptamers for both early diagnosis and therapy of various eye disorders, suggesting their potential to improve understanding and treatment strategies for these conditions.
$100 - $150
Hourly Rate
Complement Inhibitors for Advanced Dry Age-Related Macular Degeneration (Geographic Atrophy): Some Light at the End of the Tunnel?
London, UK
2 hours ago
1 Received
- Recent clinical trials show that pegcetacoplan and avacincaptad pegol, which inhibit C3 and C5 respectively, can reduce GA growth by around 20% in a dose-dependent manner.
- However, while these treatments slow the progression of GA, they do not improve visual function and may lead to serious side effects like conversion to other eye diseases and retinal issues.
$100 - $150
Hourly Rate
Piloting a forced-choice task to elicit treatment preferences in geographic atrophy.
London, UK
2 hours ago
1 Received
- Geographic Atrophy (GA) is a severe form of dry age-related macular degeneration causing significant blindness, with new intravitreal therapies, like pegcetacoplan and avacincaptad pegol, recently approved in the US that slow GA progression but don't stop or reverse it.
- A study evaluated how 28 participants weighed the benefits and risks of GA treatments through a forced-choice exercise, highlighting a preference for less frequent treatments that may harbor lower risks, even if they are slightly less effective.
- The findings illustrate the complex, personal decision-making involved in choosing GA treatments, showing how different individuals prioritize factors like treatment frequency and potential side effects differently.
$100 - $150
Hourly Rate
Avacincaptad Pegol: First Approval.
London, UK
2 hours ago
1 Received
- Avacincaptad pegol (IZERVAY™) is a drug developed by IVERIC Bio, designed to inhibit complement C5 for treating geographic atrophy related to age-related macular degeneration.
- * Recently, it has been approved for use in adults suffering from this condition.
- * The article outlines the key development milestones that contributed to its approval for treating geographic atrophy.
$100 - $150
Hourly Rate
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
London, UK
2 hours ago
1 Received
- Geographic atrophy is a severe type of dry age-related macular degeneration that can cause significant vision loss, and this study evaluates the safety and effectiveness of avacincaptad pegol 2 mg in slowing its progression.
- The GATHER2 trial was a comprehensive, double-masked, sham-controlled study conducted over 24 months, involving 448 participants aged 50 and older, divided into two groups receiving either the treatment or a sham injection.
- Results showed a significant reduction in the growth of geographic atrophy lesions in patients receiving avacincaptad pegol compared to those who received the sham treatment over 12 months.
$100 - $150
Hourly Rate
Investigational drugs inhibiting complement for the treatment of geographic atrophy.
London, UK
2 hours ago
1 Received
- - Geographic atrophy (GA) is a serious form of age-related macular degeneration (AMD) that causes significant vision loss, creating a need for new treatment methods since traditional options are limited.
- - The article reviews investigational drugs aimed at inhibiting the complement system, focusing on two recently FDA-approved drugs: pegcetacoplan (a C3 complement inhibitor) and avacincaptad pegol (a C5 complement inhibitor) with insights on their effectiveness and safety.
- - While the FDA's approval of these drugs represents a major advancement in GA treatment, inconsistent clinical trial results highlight the complexity of GA and the necessity for careful patient selection and further research to improve treatment outcomes.
$100 - $150
Hourly Rate
Treatment of dry age-related macular degeneration: A review.
London, UK
2 hours ago
1 Received
- Age-related macular degeneration (AMD) is a widespread eye disease that significantly affects society, particularly impacting vision in older adults.
- The introduction of anti-VEGF therapy has greatly improved treatment for neovascular AMD (nAMD), and research is ongoing for effective therapies for dry AMD (dAMD).
- Clinical trials are exploring various treatment options for dAMD, including anti-complement factors like pegcetacoplan and avacincaptad pegol, which have shown promise in reducing the growth of geographic atrophy.
$100 - $150
Hourly Rate
Treating patients with geographic atrophy: are we there yet?
London, UK
2 hours ago
1 Received
- Geographic atrophy (GA) is a degenerative eye disease mainly affecting people over 50, influenced by factors like age, smoking, and genetics, especially those related to the complement system.
- Recent developments in treatment, such as the FDA-approved pegcetacoplan, a complement C3 inhibitor, represent significant progress, with other therapies currently in clinical trials.
- The review offers an overview of GA, detailing risk factors, prevalence, genetic links, and imaging, while emphasizing the need for personalized treatment approaches and ongoing evaluation of new therapies.
$100 - $150
Hourly Rate
The complement system: a novel therapeutic target for age-related macular degeneration.
London, UK
2 hours ago
1 Received
- The FDA has approved pegcetacoplan and avacincaptad pegol as new therapies targeting the complement system to slow the progression of geographic atrophy (GA) in age-related macular degeneration (AMD).
- The article reviews the complement system’s role in AMD and discusses various therapies in development, including monoclonal antibodies and gene therapies, focusing on components that play critical roles in complement activation.
- While targeting the complement system shows promise in improving visual outcomes for GA, there are concerns about potential risks, such as exudative conversion, highlighting the need for further research on treatment guidelines.
$100 - $150
Hourly Rate
Can intravitreal injections with higher volume cause higher intraocular eye pressure? Considerations for anti-complement injections in normal and glaucomatous eyes.
London, UK
2 hours ago
1 Received
- - The approval of Syfovre® and Iverzay® for geographic atrophy (GA) is a major breakthrough in treating retinal diseases, as they both act as complement inhibitors.
- - Concerns about increased intraocular pressure (IOP) from the larger volume of intravitreal injections (IVI) for GA treatment are raised, as previous studies indicate even small injections can cause temporary IOP spikes.
- - To monitor and manage these IOP changes effectively, it's recommended to conduct routine evaluations using various imaging techniques before starting treatment with these new medications, while further research is needed on long-term impacts.
$100 - $150
Hourly Rate
Avacincaptad Pegol Sodium.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate